ABSTRACT

Depression is an affective condition that puts people's health at risk, with considerable and chronic depression as its principal clinical hallmark. Depression is a serious health issue that primary care physicians frequently encounter. Primary care clinicians have a crucial role in the treatment of depression and its associated medical comorbidities, but they experience difficulties in detecting and treating the disorder. We present a method for diagnosing depression that considers current evidence-based criteria and puts them into practise. Prescriptions for antidepressants are steadily increasing. The fact that they may be used off-label is one of the causes behind this development. Non-indicated usage, which incorporates different doses or durations than what is recommended, as well as medicine repurposing, accounts for up to one-third of all prescriptions. The five kinds of antidepressants are discussed, as well as their methods of action and major adverse effects. The most prevalent antidepressant off-label applications are covered. When antidepressants are used to treat different disorders, depression is frequent comorbidity, although effective therapeutic results have been reported even when depression isn't really present. Finally two different antidepressants are developed and they approved from FDA and it was released into the market immediately those are esketamine nasal spray and brexanolone I.V Injection are discussed below. Keywords: Formalized assessment and intensity evaluation, electroencephalography, off-labelled drugs, esketamine, brexanolone
Publication date: 01/07/2023

https://ijbpas.com/pdf/2023/July/MS_IJBPAS_2023_7245.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.7.7245